Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.32 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20055159 | 1.00 | CYP2D6 (0.41) | CYP2D6SMN1; SMN2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL10052320 | 0.87 | CYP2D6 (0.40) | CYP2D6SMN1; SMN2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL14705114 | 0.82 | CYP2D6 (0.32) | CYP2D6 | |
| SCHEMBL14853060 | 0.79 | CYP2D6 (0.36) | CYP2D6SMN1; SMN2TAS1R3TAS1R1 | |
| SCHEMBL19318582 | 0.79 | CYP2D6 (0.43) | CYP2D6SMN1; SMN2TAS1R3TAS1R1CA12 | |
| SCHEMBL12061932 | 0.79 | CYP2D6 (0.36) | CYP2D6SMN1; SMN2TAS1R3TAS1R1 | |
| SCHEMBL21366071 | 0.79 | CYP2D6 (0.65) | CYP2D6CA12CA14CA1CA2 | |
| SCHEMBL21729501 | 0.79 | CYP2D6 (0.65) | CYP2D6CA12CA14CA1CA2 | |
| SCHEMBL12061912 | 0.76 | CYP2D6 (0.38) | CYP2D6SMN1; SMN2CA12CA1CA2 | |
| SCHEMBL20221233 | 0.76 | CYP2D6 (0.41) | CYP2D6SMN1; SMN2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190002480-A1 | Silane-Containing Heterocyclic Compounds and Methods of Use Thereof for the Treatment of Viral Diseases | MERCK SHARP & DOHME CORP. (US) | 2019-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002480-A1 | Silane-Containing Heterocyclic Compounds and Methods of Use Thereof for the Treatment of Viral Diseases | HAVCR2, SULT2A1, HBB | CYP2D6 785/4885SMN1; SMN2 1240/4885TAS1R3 1335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.